Working at the MHRA A day in the life of a Pharmaceutical Assessor

Size: px
Start display at page:

Download "Working at the MHRA A day in the life of a Pharmaceutical Assessor"

Transcription

1 Working at the MHRA A day in the life of a Pharmaceutical Assessor. Seun Sogbesan, Associate Pharmaceutical Assessor 16 th April 2015

2 Presentation Aims To provide an insight into the day-to-day role of a pharmaceutical assessor To do some myth-busting To encourage you to consider working for the MHRA 2

3 The Agency s vision We protect and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research. 3

4 MHRA The Regulatory Body UK Regulatory Agency & Licensing Authority for medicines and medical devices Represents the UK on international bodies, which work to set consistent standards for medicines and medical devices world wide Involved in procedures for over 1000 new applications (both generics and new active substances) in

5 To obtain a UK Marketing Authorisation The company prepares and submits a dossier (Common Technical Document) CTD describes the product from discovery through to commercialisation CTD consists of 5 modules module 1: Administration information module 2: Expert Overall Summaries module 3: Quality (Chemistry, Manufacturing and Controls) module 4: Toxicological/Preclinical module 5: Clinical dossiers are professionally assessed against QUALITY, SAFETY & EFFICACY increasingly, applications are being granted on a pan European basis [centralised procedure/decentralised procedure/mutual recognition procedure] 5

6 Pharmaceutical Assessors (PAs) Within Product Licensing, a large team of assessors work within the Clinical Trials unit, Biologicals unit, Parallel Imports unit and Product Life-cycle Assessment Teams Pharmaceutical/Quality assessors work as part of a multidisciplinary team alongside clinical, non-clinical and statistics and pharmacokinetics assessors (as required) Role: to assess the quality aspects of both initial and variation applications for marketing and take decisions on their suitability for approval 6

7 A day in the life Start by planning day s work around upcoming deadlines The rest of the day may be taken up with; assessing a new application for a product tablet, parenteral, inhaler, cream, patch assessing a proposed change to the licence presenting a challenging product/potential rejection to an Expert Committee e.g. CHM 7

8 A day in the life discussing an observation with colleagues in Inspectorate Providing scientific advice to an company Training sessions/cpd seminars Corresponding with applicants/european colleagues Flexibility and time management are key 8

9 Assessing the CMC section of an application A good oversight of Chemistry, Manufacturing and Controls (drug substance and product) is required. PAs also assess product information (SPC, PIL and labelling). Focus on breadth Credit for images: Shutterstock 9

10 Typical background of assessors (pharmaceutical) Pharmaceutical assessors are required to be EU registered pharmacists (exception for work in Biologicals) Typically an assessor might hold a PhD or have a good level of relevant experience e.g. manufacturing, R&D (chemical or pharmaceutical development), quality control, regulatory affairs Some assessors have a background in practice within hospital or community pharmacy 10

11 My career path up to now 11

12 The best thing about being an assessor 12

13 Key skills required Passion for science and quality medicines Attention to detail Analytical thinking Strong written and verbal communication skills Willingness to learn Ability to manage work and work flexibly to meet deadlines 13

14 Applying for pharmaceutical assessor roles Sign up to receive alerts for MHRA jobs, join the MHRA LinkedIn page Jobs are often advertised in the Pharmaceutical Journal, TOPRA website and LinkedIn Read more about the work of the Agency on the website e.g. work with ebola, e-cigarettes cines-and-healthcare-products-regulatory-agency Read up on drug regulation in the EU and the legal basis, dossier content, guidelines such as ICH Public assessment reports are published online 14

15 APS Regulatory Focus Group Available to APS members at no extra cost Can sign up online: My account -> Join focus group Real opportunity to contribute and shape this group COMING UP Regulatory Essentials: aimed at scientists fairly early in careers (Autumn 2015) For more information and to suggest topics; or via APS 15

16 Additional Slides 16

17 MHRA - Overview Organisational structure 17

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK Presented by: Mariam Aslam ESCOP European Scientific Cooperative On Phytotheapy (ESCOP) Founded in June 1989 as an umbrella

More information

Quality, Safety and Sourcing in Unlicensed Medicines

Quality, Safety and Sourcing in Unlicensed Medicines Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?

More information

Response to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014

Response to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014 Responseto ScottishGovernment AConsultationonElectronicCigarettesand StrengtheningTobaccoControlinScotland December2014 Contact Janice Oman Scotland Representation Manager National Pharmacy Association

More information

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus

More information

REPUBLIC OF KENYA MINISTRY OF MEDICAL SERVICES PHARMACY AND POISONS BOARD

REPUBLIC OF KENYA MINISTRY OF MEDICAL SERVICES PHARMACY AND POISONS BOARD REPUBLIC OF KENYA MINISTRY OF MEDICAL SERVICES PHARMACY AND POISONS BOARD Ensuring the provision of quality, safe and efficacious pharmaceutical products and services. FUNCTIONS OF THE BOARD BACKGROUND

More information

Clinical Trials in Third Countries

Clinical Trials in Third Countries Clinical Trials in Third Countries meeting, 29 January 2015 Presented by Fergus Sweeney European Medicines Agency An agency of the European Union Overview Distribution of clinical trials submitted in support

More information

Use of unlicensed medicines and off-label uses

Use of unlicensed medicines and off-label uses Use of unlicensed medicines and off-label uses 25 Promoting hope and wellbeing together What is this leaflet about? Your doctor or pharmacist has given you this leaflet because a medicine that you have

More information

Name: Ben Cottam Job title: Policy and Communications Officer

Name: Ben Cottam Job title: Policy and Communications Officer Name: Ben Cottam Job title: Policy and Communications Officer Organisation/Institution: Faculty of Pharmaceutical Medicine Is this input submitted as an organisational or individual response? Organisational

More information

The Committee for Medicinal Products for Human Use

The Committee for Medicinal Products for Human Use www.eurordis.org The Committee for Medicinal Products for Human Use Patrick Salmon IMB Barcelona, 20 June, 2013 2 EURORDIS SUMMER SCHOOL 2013 CHMP CHMP... What is it? 3 EURORDIS SUMMER SCHOOL 2013 CHMP

More information

Frequently asked questions

Frequently asked questions 13 February 2017 EMA/527628/2011 Rev. 1 Directorate This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question

More information

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) April 26 th 2018 Raxone tablets

More information

Herbal medicines and supplements for cancer patients

Herbal medicines and supplements for cancer patients Herbal medicines and supplements for cancer patients Questions and answers Information for patients Pharmacy page 2 of 8 This leaflet is for all patients having treatment for cancer who are taking or thinking

More information

The Danish Medicines Agency s availability strategy

The Danish Medicines Agency s availability strategy låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images

More information

The European Medicines Agency (EMA)

The European Medicines Agency (EMA) The European Medicines Agency (EMA) Nathalie Bere Patient Relations Public Engagement Department EMA Training Day 29 November, 2016 An agency of the European Union What is the European Medicines Agency

More information

The Committee for Medicinal Products for Human Use

The Committee for Medicinal Products for Human Use www.eurordis.org The Committee for Medicinal Products for Human Use Patrick Salmon HPRA Barcelona, 4th June, 2015 2 CHMP 3 CHMP Move 4 The New CHMP 5 Where it all happens! 6 CHMP... What is it? CHMP What

More information

Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/

Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/ Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets (Eprosartan mesilate) PL 37222/0027-29 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Steps

More information

Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice

Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice December 2017 Contents FOREWORD... 4 1. EXECUTIVE SUMMARY... 6 2. INTRODUCTION... 9 3. BACKGROUND... 12 4. LICENSING...

More information

A Guide to the Scottish Medicines Consortium

A Guide to the Scottish Medicines Consortium A Guide to the Scottish Medicines Consortium Providing advice about newly licensed medicines www.scottishmedicines.org About the Scottish Medicines Consortium The Scottish Medicines Consortium (SMC) provides

More information

Guideline on influenza vaccines submission and procedural requirements

Guideline on influenza vaccines submission and procedural requirements 1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module

More information

Summary of product characteristics (SmPC)

Summary of product characteristics (SmPC) Summary of product characteristics (SmPC) What is it and what does it contain? An agency of the European Union Table of contents 1.What is the summary of product characteristics (SmPC)? 2.Where SmPC information

More information

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines

More information

UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS DDL2017 6-8 December 2017 Presented by Claudia Vincenzi on 7 December 2017 Quality Office EMA An agency of the European

More information

EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS

EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS European Medicines Agency London, 21 August 2006 Doc. Ref. EMEA/214301/2006 EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS

More information

Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS

Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS England commissioned services. Chief Dental Officer England:

More information

Bioequivalence Requirements: USA and EU

Bioequivalence Requirements: USA and EU Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,

More information

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure 1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza

More information

quality and safety of pharmacy preparations in Europe

quality and safety of pharmacy preparations in Europe quality and safety of pharmacy preparations in Europe Henk Scheepers, Pharm D, Senior-Inspector Public Health Supervisory Service Health Care Inspectorate The Netherlands 1 Nothing to disclose 2 1 quality

More information

Summary Public Assessment Report. Generics. Fluoxetina Aurobindo PT/H/1137/ /DC. Date:

Summary Public Assessment Report. Generics. Fluoxetina Aurobindo PT/H/1137/ /DC. Date: Summary Public Assessment Report Generics 20 mg, 60mg Capsules, hard (fluoxetine hydrochloride) PT/H/1137/001-002/DC Date: 11-11-2014 1/7 Summary Public Assessment Report Generics Fluoxetin hydrochloride,

More information

Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation

Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation Workshop on Paediatric Formulations For Assessors in National Regulatory Agencies

More information

PHARMACEUTICAL SCIENCES (PHM SCI)

PHARMACEUTICAL SCIENCES (PHM SCI) Pharmaceutical Sciences (PHM SCI) 1 PHARMACEUTICAL SCIENCES (PHM SCI) PHM SCI 310 DRUGS AND THEIR ACTIONS Introduces students to the biological effects of drugs on human health. Emphasis on how drugs,

More information

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical

More information

Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES

Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES Issue: March 2016 PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES PROFESSIONAL STANDARDS AND GUIDANCE FOR ADVERTISING MEDICINES AND PROFESSIONAL SERVICES CONTENTS

More information

Algorithms for Symptom Management. In End of Life Care

Algorithms for Symptom Management. In End of Life Care Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the

More information

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management

More information

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State Ref:11.11.24E 007 PGEU Response Consultation on measures for improving the recognition of medical prescriptions issued in another Member State PGEU The Pharmaceutical Group of the European Union (PGEU)

More information

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Forthyron

More information

Summary Public Assessment Report. Generics. Amiodarona Aurobindo. 200 mg, Tablets. (Amiodarone hydrochloride) PT/H/1444/001/DC

Summary Public Assessment Report. Generics. Amiodarona Aurobindo. 200 mg, Tablets. (Amiodarone hydrochloride) PT/H/1444/001/DC Summary Public Assessment Report Generics 200 mg, Tablets (Amiodarone hydrochloride) Summary PAR Generics 1/9 Summary Public Assessment Report Generics 200 mg, Tablets Amiodarone hydrochloride 200 mg,

More information

Blanka Hirschlerová. EDQM CEP conference Prague, Czech Republic

Blanka Hirschlerová. EDQM CEP conference Prague, Czech Republic 1 Experience with CEPs from a European regulatory authority perspective Blanka Hirschlerová EDQM CEP conference Prague, Czech Republic 2012 STATE INSTITUTE FOR DRUG CONTROL Agenda 2 Agenda Introduction

More information

Case-by-Case Regulatory toxicology testing in Drug Development in Rare or Debilitating Disease

Case-by-Case Regulatory toxicology testing in Drug Development in Rare or Debilitating Disease Case-by-Case Regulatory toxicology testing in Drug Development in Rare or Debilitating Disease David R Jones Expert Pharmaco-Toxicologist MHRA www.mhra.gov.uk David.jones@mhra.gsi.gov.uk ANY OPINIONS EXPRESSED

More information

Using medicines beyond licence

Using medicines beyond licence Using medicines beyond licence Information for patients Prepared on behalf of the Association for Palliative Medicine and the British Pain Society. November 2005 To be reviewed in November 2008. Copyright:

More information

Heng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare

Heng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare Heng-Jung Lien Section Chief Division of Medicinal Products, Food and Drug Administration, Ministry of Health and Welfare, Taiwan, R.O.C. 衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and

More information

Other EU Activities Contributing to Harmonization of Labeling

Other EU Activities Contributing to Harmonization of Labeling Other EU Activities Contributing to Harmonization of Labeling Dr Laurent Brassart European Medicines Agency Medical Information Sector DIA Labeling Harmonisation 2011 Workshop October 13-14. 2011 Disclaimer

More information

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH 11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims

More information

Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018

Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018 4 December 2017 EMA/CHMP/CVMP/QWP/504882/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work plan for the joint CHMP/ CVMP Quality

More information

The English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK)

The English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK) The English experience in a European regulatory context E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK) Declaration of Interest ASH (UK) is a public health charity

More information

Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier

Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier Section 1: General information Purpose The Ministry of Health is solely responsible for the analysis and advice set

More information

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU Primary and Community Care Directorate Pharmacy Division T: 0131-244 2518 F: 0131-244 2375 E: bill.scott@scotland.gsi.gov.uk 25 September 2009 abcdefghijklmnopqrstu = 1. Medical Directors NHS Boards 2.

More information

How is the introduction of a new medicine regulated in the UK?

How is the introduction of a new medicine regulated in the UK? Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) A medicine called Raxone, which

More information

Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017

Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017 Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017 Prof. Dr. Werner Knöss, Dr. Jacqueline Wiesner TradReg2017 Germany September 2017 Page 1 Federal Institute for

More information

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA Global Pediatric Development: We Are Making Progress PMDA Perspective Junko Sato, PhD PMDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter

More information

Ensuring the gap between science and practice is filled safely - MHRA

Ensuring the gap between science and practice is filled safely - MHRA Safeguarding public health Ensuring the gap between science and practice is filled safely - MHRA Diane Leakey Head of Information and Communications, MHRA April 2012 Agenda Who is MHRA? Why we have regulation?

More information

Update on Australian regulatory framework for medical devices

Update on Australian regulatory framework for medical devices MTAA Update on Australian regulatory framework for medical devices Val Theisz, MSc, RAC Director Regulatory Affairs, MTAA April 2017 Who is MTAA? The Medical Technology Association of Australia (MTAA)

More information

Standard Operating Procedures (SOP) Research and Development Office

Standard Operating Procedures (SOP) Research and Development Office Standard Operating Procedures (SOP) Research and Development Office Title of SOP: GCP Inspection Procedures (MHRA) SOP Number: 15 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review

More information

Herbal Medicinal Products in Europe - Harmonisation Achieved?

Herbal Medicinal Products in Europe - Harmonisation Achieved? EUROPEAN CONFERENCE Herbal Medicinal Products in Europe - Harmonisation Achieved? 13-14 November 2007, Berlin, Germany SPEAKERS: Dr Linda Anderson, MHRA, UK Gauthier Caron, Merck Consumer Health Care,

More information

Patient Group Directions Policy

Patient Group Directions Policy Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This

More information

Guideline scope Smoking cessation interventions and services

Guideline scope Smoking cessation interventions and services 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Smoking cessation interventions and services This guideline

More information

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016 15 December 2016 Committee for Medicinal Products for Human Use (CHMP) Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack Decentralised Procedure Public Assessment Report Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack Memantin-ratiopharm Starterpackung 5 mg /10 mg /15 mg /20 mg Filmtabletten ;10 mg/20 mg Filmtabletten

More information

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Regulatory Framework for Medical Devices in South Africa 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and

More information

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential

More information

How Clinical Trials Work

How Clinical Trials Work A Guide to: How Clinical Trials Work Clinical trials are rigorously controlled tests designed to examine the safety and / or effectiveness of medicines, devices, treatments, or preventive measures in humans.

More information

Update from FDA Office of Regulatory Affairs

Update from FDA Office of Regulatory Affairs Update from FDA Office of Regulatory Affairs Ellen F. Morrison Assistant Commissioner for Medical Products and Tobacco Operations Office of Regulatory Affairs U.S. Food and Drug Administration 1 The Impact

More information

Towards tailored and targeted asthma self-management using mobile technologies

Towards tailored and targeted asthma self-management using mobile technologies Towards tailored and targeted asthma self-management using mobile technologies Funded by the European Union Asthma: the problem Asthma is a lifelong chronic disease caused by inflammation of the airways,

More information

Pandemic lessons learnt

Pandemic lessons learnt Pandemic lessons learnt PCWP-HCPWG Joint meeting 28 February 2012 Presented by: Ragini Shivji, Monika Benstetter EMA An agency of the European Union Overview of presentation Background & Objective European

More information

Specific Challenges for Orphan Drugs with Paediatric Development

Specific Challenges for Orphan Drugs with Paediatric Development Specific Challenges for Orphan Drugs with Paediatric Development Tsveta Schyns-Liharska, PhD ENRAH Member of the PDCO, EMA Representing Patients and EURORDIS Disclaimer Some of the slides in this presentation

More information

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting The Pharmacovigilance Risk Assessment Committee (PRAC) Meeting 7-10 July 2014 Finalised safety procedure for methadone products containing povidone Only high molecular weight povidone was associated with

More information

Summary Public Assessment Report. Generics. Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC

Summary Public Assessment Report. Generics. Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC CMDh/305/2013 July 2014, Rev.01 Summary Public Assessment Report Generics Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC Date: 17 th August, 2016 Summary PAR Generics 1/3 Summary

More information

Changing practice to support service delivery

Changing practice to support service delivery Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction

More information

The European Medicines Agency (EMA)

The European Medicines Agency (EMA) The European Medicines Agency (EMA) Nathalie Bere and Maria Mavris Public Engagement Department EMA Training Day 21 November, 2017 An agency of the European Union What is the European Medicines Agency

More information

Regulatory update on guidelines relevant to paediatric formulations

Regulatory update on guidelines relevant to paediatric formulations Regulatory update on guidelines relevant to paediatric formulations Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Piotr Kozarewicz Scientific Administrator Quality of Medicines

More information

Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists

Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists 1 2 Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists require further guidance on medication stability? 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

More information

Overview Consumer Health Products Law and Compliance Issues

Overview Consumer Health Products Law and Compliance Issues Overview Consumer Health Products Law and Compliance Issues The First Asia Pacific Pharmaceutical Compliance Congress September 2011 CHONG JIN NG Assistant General Counsel Asia Shared Legal Services Consumer

More information

SOP-QA-30 V Scope

SOP-QA-30 V Scope Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Joanne Rodger, Senior R&D Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys,

More information

Decentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC

Decentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC Applicant: Reckitt Benckiser Reference

More information

Workshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation

Workshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation Dr. Anja Holm Chair of CVMP, EMA Danish Medicines Agency Copenhagen, DK - Denmark anh@dkma.dk Overview of existing structures relevant for Veterinary Products Regional Structures: Europe European Medicine

More information

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE This guidance document contains Assured Advice under the ACS Primary Authority Scheme. For more details visit www.acs.org.uk/assured-advice STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE Laws regulating

More information

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance 31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April

More information

Volunteer - Supporter. Care team

Volunteer - Supporter. Care team Volunteer - Supporter Care team We are Bloodwise, the largest UK blood cancer charity. Every year we stop more people dying of blood cancer and our researchers are even working to stop people developing

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

Hearing aid dispenser approval process review Introduction Hearing aid dispenser data transfer... 6

Hearing aid dispenser approval process review Introduction Hearing aid dispenser data transfer... 6 Hearing aid dispenser approval process review 2010 11 Content 1.0 Introduction... 4 1.1 About this document... 4 1.2 Overview of the approval process... 4 2.0 Hearing aid dispenser data transfer... 6 2.1

More information

Experience of paediatric formulations in Marketing Authorisatrion Applications

Experience of paediatric formulations in Marketing Authorisatrion Applications Experience of paediatric formulations in Marketing Authorisatrion Applications Elisabeth RICCHI Senior Quality Assessor 1 Overview of the presentation Formulation Measuring device Reconstitution packaging

More information

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the

More information

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT. FERROFERON 200 mg/ml. Date:

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT. FERROFERON 200 mg/ml. Date: Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE

More information

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Agnus castus oral drops Tincture of Agnus castus fruit TR2309/017/001 A. Vogel Ireland Limited 28 November 2018 CRN008R68

More information

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE

STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE STANDARDISED PACKAGING AND TOBACCO PRODUCTS DIRECTIVE Laws regulating the sale of tobacco products across the UK are changing. This guidance outlines how retailers must comply with the new regulations.

More information

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS AGENCE NATIONALE DU MEDICAMENT VETERINAIRE 8 rue Claude Bourgelat Parc d activités de la grande Marche Javené CS 70611 35306 FOUGERES MUTUAL RECOGNITION

More information

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business to Facilitate Compliance with Regulations 5(1)(g), 6, 8 and 11 of the Regulation of Retail Pharmacy Businesses

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM

More information

On the use of Amalgam for dental fillings in Sweden

On the use of Amalgam for dental fillings in Sweden On the use of Amalgam for dental fillings in Sweden Director Medical Devices Medical Products Agency Uppsala, Sweden Content of this presentation Short regulatory introduction Current use of Amalgams in

More information

Decision Making Across the Lifespan

Decision Making Across the Lifespan 40th Annual Meeting EXHIBIT AND SPONSORSHIP October 14-17, 2018 Fairmont The Queen Elizabeth Montreal, QC, Canada Decision Making Across the Lifespan 2018 OCTOBER 14th - 17th SMDM 390 Amwell Road, Suite

More information

AESGP views. Johannes Koch, Head of European Policy and International Affairs German Medicines Manufacturers' Association BAH. Who is AESGP?

AESGP views. Johannes Koch, Head of European Policy and International Affairs German Medicines Manufacturers' Association BAH. Who is AESGP? The international Generic Drug Regulators Programme (IGDRP): an initiative to further strengthen collaboration, promote regulatory convergence and improve worksharing at a worldwide level EDQM premises

More information

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015

Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and

More information

JOB DESCRIPTION JOB TITLE: STATUS: HOURS: SALARY: HOLIDAY: LOCATION: REPORTS TO: DIRECT REPORTS: KEY INTERNAL RELATIONSHIPS:

JOB DESCRIPTION JOB TITLE: STATUS: HOURS: SALARY: HOLIDAY: LOCATION: REPORTS TO: DIRECT REPORTS: KEY INTERNAL RELATIONSHIPS: JOB DESCRIPTION JOB TITLE: Senior Policy and Public Affairs Officer STATUS: Permanent contract HOURS: 37.5 hours per week 9:00am 5:30pm (JDRF operates a flexible working hours policy) SALARY: 29,800 per

More information

TCIs are only available on prescription and are usually started by a dermatology specialist.

TCIs are only available on prescription and are usually started by a dermatology specialist. (TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:

More information

Carolyn Savage Head of Communications and Events National Apprenticeship Service UVAC/ESFA HIGHER EDUCATION NEW APPRENTICESHIP PROVIDER EVENT

Carolyn Savage Head of Communications and Events National Apprenticeship Service UVAC/ESFA HIGHER EDUCATION NEW APPRENTICESHIP PROVIDER EVENT Carolyn Savage Head of Communications and Events National Apprenticeship Service UVAC/ESFA HIGHER EDUCATION NEW APPRENTICESHIP PROVIDER EVENT Contents Update on Apprenticeship campaign and work with UCAS

More information

4. The School is committed to the prevention of substance misuse through education and support. PROCEDURE

4. The School is committed to the prevention of substance misuse through education and support. PROCEDURE BISHOP WORDSWORTH S SCHOOL SUBSTANCE USE AND MISUSE POLICY Note: Parent(s) includes guardian(s) or any person who has parental responsibility for the boy or who has care of him. 1. General. This document

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Bricanyl () DK/W/0017/pdWS/001 Rapporteur: Denmark Finalisation procedure

More information